Following intense market speculation of merger discussions between Sanofi-Synthelabo and Aventis, Sanofi-Synthelabo intended to acquire Aventis shares. On the other hand, Aventis’ management has rejected the €48 B hostile bid claiming that Sanofi undervalues the company.